Latest:
Paul Jacobsen Discusses Survivorship Care Plans
Paul Jacobsen, from the H. Lee Moffitt Cancer Center and Research Institute, Discusses Survivorship Care Plans
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Paul D. Nathan, MBBS, PhD, FRCP
Latest:
Dr Nathan on the Design of the IMCgp100-202 Trial in Uveal Melanoma
Paul D. Nathan, MBBS, PhD, FRCP, discusses the design of the phase 3 IMCgp100-202 trial of tebentafusp-tebn in patients with previously untreated, HLA-A*02:01–positive metastatic uveal melanoma, highlighting the key enrollment criteria of the randomized, open-label study.
Paul Dent, PhD
Latest:
VCU Explores Novel Combos for Solid Tumors
Studies conducted at VCU Massey Cancer Center
in Richmond, Virginia, over the past 7 years
have developed the therapeutic combination of
pemetrexed and sorafenib (Nexavar) from
the bench to the bedside, and now into phase II clinical
trial evaluation.
Paul G. Corn, MD, PhD
Latest:
Dr. Corn on Possibility of Immunotherapy for Patients With Prostate Cancer
Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the possibility of immunotherapy in patients with prostate cancer.
Paul G. Richardson, MD
Latest:
Dr Richardson on the Potential Significance of Mezigdomide in Relapsed/Refractory Multiple Myeloma
Paul G. Richardson, MD, discusses how the continued development of the novel agent mezigdomide could affect the treatment paradigm for patients who progressed on, and developed resistance to, other available BCMA-directed therapies.
Paul H. Sugarbaker, MD, FACS, FRCS
Latest:
Dr. Sugarbaker on Perioperative Chemotherapy in Gastrointestinal Cancer
Paul H. Sugarbaker, MD, FACS, FRCS, chief of the peritoneal surface malignancy program and director of the Center for Gastrointestinal Malignancies at MedStar Washington Hospital Center, discusses the use of perioperative chemotherapy in the treatment of patients with gastrointestinal (GI) cancer.
Paul J. Shaughnessy, MD
Latest:
Shifting Treatment Paradigms in R/R ALL
Panelists discuss how minimal residual disease (MRD) outcomes with obecabtagene autoleucel (obe-cel) compare with those with brexucabtagene autoleucel (brexu-cel) and how the FDA approval of obe-cel may impact treatment decisions in relapsed/refractory acute lymphoblastic leukemia (R/R ALL), including considerations for patient factors, such as MRD status, Philadelphia status, and high-risk features.